Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay?
Over the past decade, an increasing number of oncology medicines with indications for multiple cancer types have been delivering benefits to patients. To ensure these products reach patients, pricing and reimbursement systems have had to adapt to address the value assessment, time-to-access, afforda...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2001-6689/13/1/2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849342719918342144 |
|---|---|
| author | Hannah Armstrong Angelina Petrova Tim Wilsdon Henriette Homoki Alexander Roediger |
| author_facet | Hannah Armstrong Angelina Petrova Tim Wilsdon Henriette Homoki Alexander Roediger |
| author_sort | Hannah Armstrong |
| collection | DOAJ |
| description | Over the past decade, an increasing number of oncology medicines with indications for multiple cancer types have been delivering benefits to patients. To ensure these products reach patients, pricing and reimbursement systems have had to adapt to address the value assessment, time-to-access, affordability, and budget uncertainty challenges this creates. Multi-year multi-indication (MYMI) agreements are made between payers and manufacturers and aim to ensure that patients have access to effective treatments for multiple conditions over time; this includes future indications of the treatment. MYMI agreements were first introduced as a solution in several European countries in 2017, offering a range of potential benefits. MYMI agreements have since demonstrated evidence of success in mitigating many of the challenges associated with assessing and reimbursing multi-indication products, time-to-patient access, and budget impact. The purpose of this article is to discuss the recent progress made with MYMI implementation across countries and provide a view on whether it is delivering for patients, healthcare systems, and innovators. We find that MYMI is not a one-size-fits-all solution but a model that needs to be adapted to the unique needs and characteristics of different healthcare systems. The intended benefits of MYMI to patients (speed and breadth of access to new indications) appear to have been realised in practice in some countries but not all. However, the administrative burden associated with MYMI implementation in some countries risks jeopardising the intended efficiency benefits. Payers and policymakers can also benefit from improved budget predictability and sustainability. |
| format | Article |
| id | doaj-art-dcc9dd5a24044ab7a73f8d1985b2bcc8 |
| institution | Kabale University |
| issn | 2001-6689 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-dcc9dd5a24044ab7a73f8d1985b2bcc82025-08-20T03:43:16ZengMDPI AGJournal of Market Access & Health Policy2001-66892025-01-01131210.3390/jmahp13010002Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay?Hannah Armstrong0Angelina Petrova1Tim Wilsdon2Henriette Homoki3Alexander Roediger4Charles River Associates, London EC2M 7EA, UKCharles River Associates, London EC2M 7EA, UKCharles River Associates, London EC2M 7EA, UKMSD International Business GmbH, 6010 Kriens, SwitzerlandMSD International Business GmbH, 6010 Kriens, SwitzerlandOver the past decade, an increasing number of oncology medicines with indications for multiple cancer types have been delivering benefits to patients. To ensure these products reach patients, pricing and reimbursement systems have had to adapt to address the value assessment, time-to-access, affordability, and budget uncertainty challenges this creates. Multi-year multi-indication (MYMI) agreements are made between payers and manufacturers and aim to ensure that patients have access to effective treatments for multiple conditions over time; this includes future indications of the treatment. MYMI agreements were first introduced as a solution in several European countries in 2017, offering a range of potential benefits. MYMI agreements have since demonstrated evidence of success in mitigating many of the challenges associated with assessing and reimbursing multi-indication products, time-to-patient access, and budget impact. The purpose of this article is to discuss the recent progress made with MYMI implementation across countries and provide a view on whether it is delivering for patients, healthcare systems, and innovators. We find that MYMI is not a one-size-fits-all solution but a model that needs to be adapted to the unique needs and characteristics of different healthcare systems. The intended benefits of MYMI to patients (speed and breadth of access to new indications) appear to have been realised in practice in some countries but not all. However, the administrative burden associated with MYMI implementation in some countries risks jeopardising the intended efficiency benefits. Payers and policymakers can also benefit from improved budget predictability and sustainability.https://www.mdpi.com/2001-6689/13/1/2multi-indicationmulti-yearaccess agreementsoncologyimmuno-oncology |
| spellingShingle | Hannah Armstrong Angelina Petrova Tim Wilsdon Henriette Homoki Alexander Roediger Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay? Journal of Market Access & Health Policy multi-indication multi-year access agreements oncology immuno-oncology |
| title | Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay? |
| title_full | Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay? |
| title_fullStr | Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay? |
| title_full_unstemmed | Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay? |
| title_short | Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay? |
| title_sort | multi year multi indication agreements for supporting patient access to oncology medicines with multiple indications an experimental approach or here to stay |
| topic | multi-indication multi-year access agreements oncology immuno-oncology |
| url | https://www.mdpi.com/2001-6689/13/1/2 |
| work_keys_str_mv | AT hannaharmstrong multiyearmultiindicationagreementsforsupportingpatientaccesstooncologymedicineswithmultipleindicationsanexperimentalapproachorheretostay AT angelinapetrova multiyearmultiindicationagreementsforsupportingpatientaccesstooncologymedicineswithmultipleindicationsanexperimentalapproachorheretostay AT timwilsdon multiyearmultiindicationagreementsforsupportingpatientaccesstooncologymedicineswithmultipleindicationsanexperimentalapproachorheretostay AT henriettehomoki multiyearmultiindicationagreementsforsupportingpatientaccesstooncologymedicineswithmultipleindicationsanexperimentalapproachorheretostay AT alexanderroediger multiyearmultiindicationagreementsforsupportingpatientaccesstooncologymedicineswithmultipleindicationsanexperimentalapproachorheretostay |